Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety of combining Sorafenib and
chemotherapy (mitoxantrone or docetaxel) in patients with AIPC.